𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B

✍ Scribed by M.C. Mendes-Correa; J.R.R. Pinho; S. Locarnini; L. Yuen; R. Sitnik; R.A.F. Santana; M.S. Gomes-Gouvêa; O.M. Leite; L.G. Martins; M.H. Silva; R.J. Gianini; D.E. Uip

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
107 KB
Volume
82
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co‐infected with HIV and hepatitis B virus (HBV). A cross‐sectional study of 847 patients with HIV was conducted. Patients provided blood samples for HBsAg detection. The load of HBV was determined using an “in‐house” real‐time polymerase chain reaction. HBV genotypes/subgenotypes, antiviral resistance, basal core promoter (BCP), and precore mutations were detected by DNA sequencing. Twenty‐eight patients with co‐infection were identified. The distribution of HBV genotypes among these patients was A (n = 9; 50%), D (n = 4; 22.2%), G (n = 3; 16.7%), and F (n = 2; 11.1%). Eighteen patients were treated with LAM and six patients were treated with LAM plus TDF. The length of exposure to LAM and TDF varied from 4 to 216 months. LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia. This pattern and an accompanying rtV173L mutation was found in four patients. Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M). Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found. No putative TDF resistance substitution was detected. The data suggest that prolonged LAM use is associated with the emergence of particular changes in the HBV genome, including substitutions that may elicit a vaccine escape phenotype. No putative TDF resistance change was detected after prolonged use of TDF. J. Med. Virol. 82:1481–1488, 2010. © 2010 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Lamivudine resistance mutations in Europ
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B
✍ Lucia Taramasso; Patrizia Caligiuri; Antonio Di Biagio; Bianca Bruzzone; Raffael 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

## Abstract Evaluation of resistance pattern in patients with chronic hepatitis B. Retrospective study of hepatitis B virus (HBV) resistance mutations in patients found viraemic after first‐line treatment. HBV viral load was determined by a real‐time polymerase chain reaction and the substitutions

Effect of HIV co-infection on mutation p
Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B
✍ Fabio Iacomi; Donatella Vincenti; Francesco Vairo; Mariacarmela Solmone; Andrea 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Abstract A retrospective review was performed comparing lamivudine‐resistance mutation patterns between patients infected with hepatitis B virus (HBV) with or without human immunodeficiency virus (HIV) co‐infection. Medical records that included a genotypic test of patients infected with HBV and

Mutations associated with lamivudine-res
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients
✍ S. Gloria Selabe; Azwidowi Lukhwareni; Ernest Song; Yeegan G.M. Leeuw; Rosemary 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract This was an exploratory study to investigate lamivudine‐resistant hepatitis B virus (HBV) strains in selected lamivudine‐naïve HBV carriers with and without human immunodeficiency virus (HIV) co‐infection in South African patients. Thirty‐five lamivudine‐naïve HBV infected patients with

Association of lamivudine-resistant muta
Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B
✍ Choong Keun Cha; Hyeok Choon Kwon; Jae Youn Cheong; Sung Won Cho; Sun Pyo Hong; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Abstract Adefovir has a potent antiviral activity as a rescue treatment against lamivudine‐resistant strains. The aim of this study was to assess the patterns of lamivudine‐resistant mutations and their influence on the virologic response to adefovir rescue therapy in patients with lamivudine‐re

Comparative analysis of hepatitis B viru
Comparative analysis of hepatitis B virus genotype a molecular evolution in patients infected with HBV and in patients co-infected with HBV and HIV
✍ L. Cassino; C. Torres; V. Mbayed; N. Laufer; R.H. Campos; J. Quarleri 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract HIV infection has a significant impact on the natural progression of liver disease caused by infection with hepatitis B virus (HBV), but its role in the molecular evolution of HBV is unknown. It is difficult to study the molecular evolution of HBV longitudinally considering its genomic

Mutations associated with the therapeuti
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis
✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated